DNA Sequencing Market is estimated to be valued at USD 8,486.7 Mn in 2025 and is expected to reach USD 18,412.4 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 11.7% from 2025 to 2032.
The DNA sequencing market is experiencing strong growth driven by rising demand across clinical diagnostics, personalized medicine, and biotechnology research. Increasing prevalence of genetic disorders, cancer, and infectious diseases has led to growing reliance on sequencing technologies for early and accurate detection. The DNA sequencing market demand is further fueled by the adoption of next-generation sequencing (NGS), which offers high-throughput analysis at lower costs and faster turnaround times compared to traditional methods. Pharmaceutical and biotech companies are investing heavily in genomic research to develop targeted therapies, while government initiatives worldwide are supporting genome mapping programs and precision healthcare.
|
Current Event |
Description and its Impact |
|
Federal Research Funding Crisis and Policy Shifts |
|
|
US-China Trade War and Geopolitical Tensions |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Artificial Intelligence (AI) is rapidly transforming the DNA sequencing market by enhancing data interpretation, accelerating analysis, and improving diagnostic accuracy. Traditional sequencing generates massive volumes of genomic data, but AI-driven algorithms can process this information far more efficiently, identifying mutations, classifying genetic variants, and predicting disease risks with higher precision. AI tools are also being integrated into next-generation sequencing (NGS) workflows to optimize base calling, reduce sequencing errors, and automate variant annotation. This has significantly shortened turnaround times in clinical and research settings. Furthermore, AI-powered platforms are enabling real-time genomic insights for personalized medicine, especially in oncology, rare diseases, and pharmacogenomics. According to recent DNA Sequencing Market Forecasts, the integration of AI and machine learning technologies is expected to be a key growth catalyst, making sequencing faster, more scalable, and more accessible across both developed and emerging markets.
In June 2025, DeepMind introduced AlphaGenome, an AI model designed to predict how single DNA variants impact gene regulation across the vast non‑coding 98% of the genome. AlphaGenome processes up to one million base‑pairs at single‑letter resolution and outputs thousands of molecular properties, including transcription start and end sites, RNA splicing, chromatin accessibility, and protein binding, using deep learning architectures built from convolutional and transformer layers.
In terms of Product Type, the consumables segment is expected to dominate the DNA sequencing market with an estimated share of 45.5% in 2025, due to their recurring usage in every sequencing run. Unlike instruments, which are one-time capital investments, consumables such as sample prep kits, reagents, flow cells, and library preparation tools are required continuously for each analysis. As the number of sequencing applications grows in clinical diagnostics, oncology, forensics, and agriculture, so does the need for high-quality, reliable consumables. Additionally, the increasing adoption of next-generation sequencing (NGS) technologies which require specialized consumables for efficient and accurate sequencing has further driven DNA sequencing market demand.
For instance, in February 2025, QIAGEN introduced a new library preparation kit engineered to support multi‑omic studies and drive advancements in precision medicine. The kit simplifies sample processing for diverse biomarkers, including DNA, RNA and proteins, enhancing throughput and compatibility across platforms. By enabling streamlined workflows and stronger data integration across genomic, transcriptomic and proteomic analyses, the solution promises greater insight into disease biology and personalized therapeutic strategies.
In terms of Technology, the Next-Generation Sequencing segment is expected to account for the most significant share of the global DNA sequencing market in 2025, due to its speed, accuracy, scalability, and cost-effectiveness. Unlike traditional Sanger sequencing, NGS allows the simultaneous sequencing of millions of DNA fragments, enabling rapid analysis of entire genomes or targeted regions. This makes it ideal for applications such as cancer genomics, rare disease diagnosis, pharmacogenomics, and infectious disease surveillance.
For instance, in February 2025, Roche launched its proprietary Sequencing by Expansion (SBX) technology, introducing a new class of next‑generation sequencing that promises ultra‑rapid, flexible and scalable DNA/RNA analysis. SBX uses synthetic expanded molecules called Xpandomers, combined with a high‑throughput CMOS sensor to sequence target molecules in hours, rather than days, with high signal‑to‑noise and single‑molecule accuracy, further propelling the DNA sequencing market share.
In terms of Application, the Oncology segment is projected to hold the highest share in the global DNA sequencing market in 2025, due to the growing need for precision diagnostics and personalized cancer treatment. DNA sequencing enables oncologists to identify specific genetic mutations, alterations, and biomarkers that are responsible for different types of cancer. This helps in tailoring therapies to target the molecular profile of an individual’s tumor, improving treatment effectiveness and patient outcomes.
With the rise of liquid biopsies and companion diagnostics, DNA sequencing allows for non-invasive monitoring of cancer progression and drug resistance. Additionally, pharmaceutical companies are leveraging sequencing to accelerate cancer drug discovery and clinical trials. The high global incidence of cancer, along with the push for more effective and early-stage diagnostics, continues to boost DNA sequencing market growth in oncology.
In February 2025, IIT Madras launched the Bharat Cancer Genome Atlas (BCGA), India’s first-ever cancer genome database focused on breast cancer, in a major leap for precision oncology. This initiative features data from 960 whole-exome sequences derived from 480 breast cancer patients collected across India under a programme.
In terms of End User, the Pharmaceutical & Biotechnology Companies segment is expected to contribute the highest share of the global DNA sequencing market in 2025, due to their increasing reliance on genomic data to accelerate drug discovery, development, and precision medicine initiatives. These companies use DNA sequencing to identify genetic mutations, biomarkers, and disease pathways, enabling the design of more targeted and effective therapies. This is particularly critical in areas like oncology, rare genetic disorders, and infectious diseases.
Next-generation sequencing (NGS) allows pharma and biotech firms to conduct high-throughput screening of genes, improving the speed and accuracy of identifying viable drug candidates. Additionally, sequencing technologies help in patient stratification for clinical trials, ensuring better outcomes and reduced failure rates. With the rising importance of personalized medicine and biologics, DNA sequencing has become an essential tool in R&D pipelines.
In April 2025, EpiCypher®, an epigenomics innovation solutions, unveiled two cutting-edge DNA methylation sequencing assays CUTANA® meCUT&RUN and Multiomic CUT&RUN, designed to advance drug discovery through high-resolution, cost-effective analysis. Together, these tools offer scalable, sensitive, and streamlined workflows that lower barriers to comprehensive epigenomic profiling in cancer biology, neuroscience, immunology, aging, and beyond.
To learn more about this report, Download Free Sample
North America is expected to dominate the market with 37.80% in 2025 driven by a combination of technological leadership, strong R&D infrastructure, and the strategic initiatives of key players. Major companies in the region, such as Illumina, Thermo Fisher Scientific, and Pacific Biosciences, are consistently launching advanced sequencing platforms and expanding their product portfolios to meet the rising demand from healthcare, pharmaceutical, and academic sectors.
For instance, in November 2025, Pacific Biosciences (PacBio) launched its Vega™ system, a benchtop version of its high‑throughput Revio long‑read sequencer. Priced at USD 169,000, Vega brings the company’s renowned HiFi accuracy (99.9%) into a compact form, enabling labs to perform long‑read sequencing without high capital investment.
The region also benefits from supportive government initiatives such as the NIH's All of Us Research Program and significant funding into genomic research, which accelerate the adoption of sequencing technologies. Additionally, North America has a high concentration of biotechnology and pharmaceutical firms that increasingly rely on DNA sequencing for precision medicine, drug discovery, and clinical trials.
For instance, in May 2025, The National Institutes of Health’s All of Us Research Program has announced expansion of individual DNA result offerings, broadening beyond ancestry and trait reports to include health-related findings like hereditary disease risk and pharmacogenomic profiles.
The Europe region is expected to be the fastest growing region over the forecast period, primarily driven by the increasing adoption of organic growth strategies by key industry players. In particular, companies operating in the region are focusing on product launches to expand and diversify their product portfolios. This strategic focus on innovation and market responsiveness is enabling firms to better address evolving consumer needs, strengthen brand presence, and capture a greater share of the market. Additionally, favorable regulatory frameworks, growing consumer awareness, and a robust industrial base further contribute to the market's expansion across Europe.
For instance, in March 2025, Spain’s National Cancer Research Centre (CNIO‑ISCIII) collaborated with the European Genome of Europe (GoE) project to help build the continent’s largest genetic database. This initiative will sequence 100,000 whole genomes from 27 countries, including 12,000 samples sourced via Spain’s IMPaCT Cohort. With a €45 million budget, approximately €3 million contributed by Spain under EU co‑funding CNIO will extract and quantify DNA from blood samples and share sequencing duties with the Spanish National Genomic Analysis Centre (CNAG).
The U.S. is the leading market for DNA sequencing, driven by major players like Illumina and Thermo Fisher Scientific, strong R&D funding from NIH, and large-scale programs like All of Us. DNA sequencing market demand is fueled by applications in precision medicine, cancer diagnostics, newborn screening, and population genomics. Robust clinical infrastructure, regulatory support, and widespread adoption in hospitals and labs make the U.S. a global leader in sequencing innovation and implementation.
For instance, in April 2025, Ultima Genomics unveiled its “Count on Us” initiative, pledging 3 trillion DNA sequencing reads, equivalent to about 9,000 human genomes at 30× coverage—to researchers at academic, public, government and non‑profit institutions across the United States and Canada. Ultima will award between 10 billion to 100 billion reads per project, prioritizing labs facing funding uncertainties.
The UK is a major player in the DNA sequencing market, driven by initiatives like Genomics England and the NHS Genomic Medicine Service, which integrate genome sequencing into routine clinical care. Programs such as the 100,000 Genomes Project have enabled large-scale sequencing for rare diseases and cancers. Demand is fueled by the push for predictive and personalized medicine, a strong public healthcare system, and close collaboration between academia, pharma, and healthcare providers.
In March 2025, UK scientists have developed a rapid DNA sequencing system aimed at combating antibiotic‑resistant “superbugs” by diagnosing bacterial infections far more quickly and accurately. Developed jointly by the Medicines & Healthcare products Regulatory Agency (MHRA) and Barts Health NHS Trust in London, the method delivers results within 48 hours, compared with the week or more required by conventional culture tests.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 8,486.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 11.7% | 2032 Value Projection: | USD 18,412.4 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Thermo Fisher Scientific, Inc., Illumina, Inc., PerkinElmer Genomics, QIAGEN, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, Macrogen, Inc., Abbott, PacBio, Zymo Research Corporation, Oxford Nanopore Technologies plc, Tecan Trading AG, Hamilton Company, ZS Genetics, Inc. LI-COR, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
DNA sequencing is a critical tool in the research and development (R&D) of new drugs, enabling pharmaceutical companies to identify genetic mutations, understand disease mechanisms, and develop targeted therapies with greater precision. This has made sequencing technologies an essential component of modern drug discovery pipelines.
As a result, there is a notable increase in R&D investments by key players aiming to expand their therapeutic portfolios, particularly in oncology, rare genetic disorders, and infectious diseases. Companies are leveraging advancements in next-generation sequencing (NGS) to accelerate biomarker discovery, enhance clinical trial design, and improve drug efficacy and safety profiling.
According to DNA sequencing market research, this trend of R&D-driven innovation is expected to significantly contribute to market growth over the forecast period. The integration of sequencing data into pharmaceutical workflows is transforming drug development timelines and increasing the demand for high-throughput, cost-effective sequencing solutions globally.
For instance, in May 2025, a new algorithm developed by EMBL‑EBI in collaboration with Genomics England and clinical partners offers faster, more reliable identification of cancer‑linked structural DNA changes using long‑read sequencing data. Traditional tools often generate false positives in complex cancer genomes, complicating diagnosis and treatment.
The DNA sequencing technology is used for the diagnosis of cancer and thus increasing prevalence of cancer is expected to drive the market growth over the forecast period. For instance, according to the American Cancer Society 2025 estimates, the total number of new cancer cases in the United States is projected to reach 2,041,910, comprising 1,053,250 males and 988,660 females. The total number of cancer-related deaths is expected to be 618,120, with 323,900 male deaths and 294,220 female deaths. Among this, Oral cavity and pharynx cancers (59,660 new cases and 12,770 deaths), digestive system (362,200 new cases and 174,520 deaths), pancreatic cancer (67,440 cases and 51,980 deaths), and many more.
One of the most promising future opportunities in the DNA sequencing market lies in the expansion of precision and personalized medicine. As healthcare shifts away from generalized treatment models, DNA sequencing is playing a critical role in enabling therapies tailored to an individual’s unique genetic profile. By uncovering specific mutations, genetic predispositions, and biomarkers, DNA sequencing allows clinicians to diagnose diseases more accurately, predict treatment response, and avoid adverse drug reactions. This is particularly impactful in areas such as oncology, where sequencing is used to identify tumor-specific mutations and guide the selection of targeted therapies. The integration of genomic data into clinical workflows, supported by falling sequencing costs and advances in bioinformatics is making personalized care more accessible and scalable. Furthermore, government-backed initiatives such as Genomics England and the All of Us Research Program in the U.S. are accelerating the mainstream adoption of genomics in population health. According to the DNA sequencing market forecast, this increasing reliance on genomics for individualized healthcare is expected to be a major growth driver over the coming years, reshaping diagnostic practices and therapeutic development across the globe.
For instance, in April 2025, India’s GenomeIndia Project completed whole‑genome sequencing of 10,000 individuals from 83 population groups, mapping over 135 million genetic variants, including 7 million previously undocumented to create the nation’s first reference genome. Researchers from more than 20 institutes, including CSIR‑CCMB and AIIMS, analysed data in Nature Genetics to illustrate how the results can improve disease diagnosis, predict drug response, and support the development of personalized medicines tailored to Indian genetic diversity.
The DNA sequencing market value is undergoing a profound transformation driven not by incremental adoption but by a decisive shift in how genomics is integrated into mainstream clinical and industrial workflows.
One of the most significant structural shifts is the growing prominence of long-read sequencing technologies. Historically, short-read platforms dominated the field due to cost efficiency; however, the inability to resolve complex genomic regions, such as structural variants and repetitive sequences, has severely limited their diagnostic potential. Oxford Nanopore and Pacific Biosciences are now gaining clinical credibility, evidenced by the recent adoption of PacBio’s Revio system by population-scale genomics projects in the U.S., Japan, and the UAE, which require accurate resolution of large-scale structural variants for polygenic disease correlation.
Moreover, we are witnessing a reallocation of sequencing investments from research institutions to hospital systems and national health bodies. For example, the UK's Genomics England initiative has expanded its remit from rare diseases to cancer genomics, reflecting a broader movement towards embedding sequencing as a core component of patient care. Similarly, in South Korea, the Ministry of Health has authorized whole genome sequencing (WGS) as a reimbursable test for certain oncology indications, a critical regulatory precedent that could catalyze reimbursement policy shifts across the OECD.
Equally noteworthy is the rising geopolitical dimension of the DNA sequencing landscape. China’s push for domestic self-reliance in biotechnology, exemplified by the rapid global scaling of MGI Tech, is fragmenting the supplier landscape and intensifying competition. MGI’s DNBSEQ platform, with cost-per-gigabase advantages and open licensing strategies, is making inroads in markets previously dominated by Illumina. This techno-sovereignty movement is likely to restructure procurement policies in Southeast Asia, Africa, and Latin America over the next five years.
Share
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
